349c48ca-ced2-42db-8a50-ea3293116623
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 49
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.510
- OXIDATIVE_PHOSPHORYLATION+0.460
- ANGIOGENESIS+0.430
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.390
- TNFA_SIGNALING_VIA_NFKB+0.390
- ADIPOGENESIS+0.370
- FATTY_ACID_METABOLISM+0.350
- INFLAMMATORY_RESPONSE+0.350
- MTORC1_SIGNALING+0.350
- PEROXISOME+0.350
Top 10 suppressed
- MITOTIC_SPINDLE-0.240
- PANCREAS_BETA_CELLS-0.230
- G2M_CHECKPOINT-0.170
- UV_RESPONSE_DN-0.140
- HEDGEHOG_SIGNALING-0.040
- TGF_BETA_SIGNALING-0.040
- UNFOLDED_PROTEIN_RESPONSE-0.030
- NOTCH_SIGNALING-0.010
- PROTEIN_SECRETION+0.000
- WNT_BETA_CATENIN_SIGNALING+0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | d25af392-21ad-4aa6-8669-34656bf71af5 | — | — | 0.892 |
| 2 | 65DAB913-D39C-4AC4-BB1C-10E58914571F | — | — | 0.877 |
| 3 | SRR6013489 | — | cohortA1 | 0.870 |
| 4 | MDT-AP-2001 | Med | Medulloblastoma | 0.856 |
| 5 | X3a5c813b.6c47.49aa.916c.bcddbafdd54b | — | cohortA1 | 0.855 |
| 6 | AUR-AFEC-TTM4-A-1-1-R-A742-41 | — | C | 0.852 |
| 7 | MDT-AP-1301 | Med | Medulloblastoma | 0.838 |
| 8 | SRR1335688 | GTEX | — | 0.837 |
| 9 | TCGA-34-5241-01A-01R-1443-07 | — | cohortSQ1 | 0.837 |
| 10 | TCGA-39-5039-01A-01R-1443-07 | — | cohortSQ1 | 0.836 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.510 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.460 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.430 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.390 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.390 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.370 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.350 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.350 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.350 | Inavolisib | — uncovered |
| PEROXISOME | 0.350 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.350 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.350 | Idelalisib | — uncovered |
| COAGULATION | 0.340 | Binimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.340 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.340 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.310 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.310 | Inavolisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| APOPTOSIS | 0.280 | Idelalisib | — uncovered |
| COMPLEMENT | 0.280 | Inavolisib | — uncovered |